問卷

TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Thoracic Medicine

Division of General Internal Medicine

Division of Hematology & Oncology

Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Division of General Internal Medicine

更新時間:2023-09-19

郭志熙Kuo, Chih-Hsi
  • Principal Investigator
  • Clinical Trial Experience (year) -18 years -3 個月

篩選

List

128Cases

2025-05-01 - 2030-04-30

Phase III

Active
A global, multicenter, randomized, open-label phase 3 trial comparing sacituzumab govitecan with standard of care (SOC) in previously treated extensive-stage small cell lung cancer (ES-SCLC) participants.
  • Condition/Disease

    ORR is defined as the percentage of participants who achieve a complete response (CR) or a partial response (PR) as assessed by BICR according to RECIST v1.1. OS is defined as the length of time elapsed from random assignment until the date of death from any cause.

  • Test Drug

    TRODELVY for Injection

Participate Sites
9Sites

Recruiting9Sites

2016-07-01 - 2020-12-31

Others

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

邱昭華
Taipei Veterans General Hospital

Division of Hematology & Oncology

楊政達
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2018-12-01 - 2027-12-31

Phase II/III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

楊政達
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2024-06-01 - 2030-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting6Sites

2020-01-01 - 2026-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2020-02-01 - 2025-12-10

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting5Sites

Terminated3Sites

2023-03-01 - 2027-12-31

Phase I/II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Not yet recruiting3Sites

2021-01-01 - 2026-06-30

Phase I

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2020-04-01 - 2025-01-31

Phase I

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting2Sites

Terminated2Sites

2022-08-01 - 2026-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting2Sites

Recruiting6Sites